Anavex Life Sciences (AVXL) Projected to Post Quarterly Earnings on Monday

Anavex Life Sciences (NASDAQ:AVXL) is projected to announce its Q2 2026 results before the market opens on Monday, May 11th. Analysts expect the company to announce earnings of ($0.07) per share for the quarter. Parties are encouraged to explore the company’s upcoming Q2 2026 earning overview page for the latest details on the call scheduled for Tuesday, May 12, 2026 at 8:30 AM ET.

Anavex Life Sciences (NASDAQ:AVXL) last posted its quarterly earnings data on Monday, February 9th. The biotechnology company reported ($0.06) EPS for the quarter, topping the consensus estimate of ($0.10) by $0.04. On average, analysts expect Anavex Life Sciences to post $0 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Anavex Life Sciences Trading Up 3.2%

NASDAQ:AVXL opened at $3.22 on Friday. Anavex Life Sciences has a 12 month low of $2.61 and a 12 month high of $13.99. The stock has a 50 day moving average of $3.72 and a two-hundred day moving average of $4.49. The firm has a market cap of $298.40 million, a P/E ratio of -7.00 and a beta of 1.24.

Wall Street Analysts Forecast Growth

AVXL has been the subject of several research reports. Rodman & Renshaw initiated coverage on Anavex Life Sciences in a research note on Monday, May 4th. They set a “buy” rating and a $20.00 price objective for the company. Wall Street Zen upgraded Anavex Life Sciences from a “sell” rating to a “hold” rating in a research note on Saturday, February 14th. HC Wainwright reiterated a “buy” rating and set a $20.00 price objective on shares of Anavex Life Sciences in a research note on Tuesday, February 10th. Weiss Ratings upgraded Anavex Life Sciences from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Wednesday, April 22nd. Finally, D. Boral Capital reiterated a “buy” rating and set a $24.00 price objective on shares of Anavex Life Sciences in a research note on Tuesday, March 31st. Three research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, the stock presently has an average rating of “Hold” and an average price target of $21.33.

Institutional Investors Weigh In On Anavex Life Sciences

Large investors have recently made changes to their positions in the stock. Schonfeld Strategic Advisors LLC purchased a new stake in shares of Anavex Life Sciences in the fourth quarter valued at approximately $164,000. Cetera Investment Advisers grew its position in shares of Anavex Life Sciences by 51.7% in the fourth quarter. Cetera Investment Advisers now owns 42,856 shares of the biotechnology company’s stock valued at $153,000 after purchasing an additional 14,598 shares in the last quarter. Mariner LLC grew its position in shares of Anavex Life Sciences by 47.3% in the fourth quarter. Mariner LLC now owns 38,821 shares of the biotechnology company’s stock valued at $138,000 after purchasing an additional 12,465 shares in the last quarter. American Century Companies Inc. purchased a new stake in shares of Anavex Life Sciences in the second quarter valued at approximately $135,000. Finally, Tower Research Capital LLC TRC grew its position in shares of Anavex Life Sciences by 215.7% in the second quarter. Tower Research Capital LLC TRC now owns 13,850 shares of the biotechnology company’s stock valued at $128,000 after purchasing an additional 9,463 shares in the last quarter. 31.55% of the stock is currently owned by hedge funds and other institutional investors.

Anavex Life Sciences Company Profile

Anavex Life Sciences Corp is a clinical?stage biopharmaceutical company focused on the development of novel therapeutics for central nervous system (CNS) disorders. The company applies a proprietary drug discovery platform that targets sigma?1 and muscarinic receptors to modulate cellular stress pathways and support neuronal function. Headquartered in New York City, Anavex is dedicated to advancing treatments for neurodegenerative and neurodevelopmental diseases with high unmet medical need.

The company’s lead product candidate, blarcamesine (ANAVEX2?73), is a small?molecule activator of the sigma?1 receptor currently being evaluated in clinical trials for Alzheimer’s disease and Parkinson’s disease dementia.